“We would like to take it to the next level, where CAR therapies become a more standardized, highly controlled treatment,” said
Mikael Dolsten,
Pfizer’s head of global research and development.
Working with French biotech
Cellectis SA,
ALCLS.FR -2.65%
Pfizer wants to develop a generic CAR therapy for use in any
patient, potentially lowering its cost. But its research is still
preclinical, and may not work in humans.
Stephen McGarry,
global head of health-care research at Société Générale, agrees
the treatments being developed by Novartis and Juno could justify
“astronomical” prices, although he thinks health-care payers and
patients might fight back.
“When you
look at the initial data with the Novartis therapy, you’re getting cures
in some kids—what do you charge for that?” he asks
No comments:
Post a Comment